Learn how this partnership aims to deliver integrated solutions for pharmaceutical clients, improving market access, pricing strategies, and RWE generation.
Updates
Learn how early HEOR evidence generation can enhance health technology development by supporting pricing, reimbursement, and market access.
The award recognizes exceptional disability inclusion practices and policies in a diverse range of industriesRESEARCH TRIANGLE PARK, N.C.
Learn how new tools, including the DIVERSE framework, enhance reliability and understanding in real-world evidence by addressing data source diversity.
Reflections on some of the key takeaways from the ISPE Annual Meeting 2024
The award recognizes commitment to creating an inclusive workplace
Life sciences innovators can lead change via integrated evidence generation
Meta Description Learn how to enhance the commercial value of your biotech innovation, from understanding payer perceptions to leveraging nonclinical value for investors.
See how companies are adjusting strategies and resources to meet the challenges of JCAs, including anticipating PICOs and aligning regulatory dossiers.
Insights on Centers for Medicare and Medicaid Services (CMS) Updates for IPAY 2027
Submission is subject to the EU HTA Regulation, which applies to all new oncology drugs and cell and gene therapies beginning January 2025, orphan medicinal products starting January 2028, and lastly, all new drugs from 2030 onward
The award recognizes RTI’s commitment to sustainability and creating a positive work environment
Contributed by: Ari Gnanasakthy, MBA, MScPrincipal Scientist, Patient-Centered Outcomes AssessmentRTI Health Solutions
Now is the time for drug manufacturers to do everything they can to get ready for a potential submission in support of their product for Medicare's Drug Price Negotiation (DPN) program.
Drug and medical device developers are looking to understand the potential implications of joint clinical assessments and Medicare price negotiations
ASCO 2024 demonstrated the incredible efforts of the oncology community to push the boundaries of cancer treatment
Big changes in US Medicare drug pricing and EU Health Technology Assessment regulations. Enter Joint Clinical Assessments.
The institute was awarded silver level recognition for its commitments to employee health
Jennifer Alkire, PharmD, Senior Associate, Value & Access, attended AMCP 2024 and brings back these insights.
The 2024 America’s Best Employers for Diversity rankings resulted from surveying 170,000 US employees
Strategic collaboration follows RTI’s equity investment in advanced tech-enabled research services
When causal inference is applied to pharmacoepidemiology, researchers can estimate which treatments are helpful or harmful.
Institute commits additional $9 million to internal sustainability investments to reduce GHG emissions